Details of Outlaw Half Holkham Elite Wave 

Details of Outlaw Half Holkham Elite Wave 

Posted by on 9th February 2017

The Outlaw Half Holkham will have an elite wave on the 2 July this summer. Competitors can opt into the elite wave, which will go off first and allow head-to-head racing between the fastest competitors. The Outlaw Half Holkham features a £1500 prize pot for course record breakers.

This is the first time we have offered an elite wave at any of the Outlaw events and it’s based on numerous requests from athletes to do so. It should create a better spectacle for people who come along to watch.

Competitors can opt into the elite wave and the aim is to have a wave of around fifty male and female athletes. It is not necessary to hold a professional racing license, or to have raced as a professional previously. Competitors in the elite wave will not be eligible for age-group prizes, but will have separate prizes for the overall top competitors. Racing in the elite wave is optional, but competitors in the age-group waves will not be eligible for overall prizes.

Time standards in priority order:

Men: 

Finished in the top ten overall at Holkham in 2016

Achieved time below 4hrs30 for a middle distance triathlon during 2016

Achieved time below 4hrs25 for a middle distance triathlon in the last five years

Stepping up from high level standard distance racing and confident of achieving times above

Women:

Finished in the top ten overall at Holkham in 2016

Achieved time below 5hrs for a middle distance triathlon during 2016

Achieved time below 4hrs55 for a middle distance triathlon in the last five years

Stepping up from high level standard distance racing and confident of achieving times above

 

Applications should be submitted to info@osbevents.com by 15 March 2017 and will be notified by 30 March. Later applications will be considered on their merit when received.

 

OSB Partners

blueseventy  Erdinger Beer  Triathlonguard  High 5  Cancer Research    blueseventy  Erdinger Beer  Raceskin Logo  High 5 Cancer Research